Kiniksa Pharmaceuticals International, plc (KNSA) company profile
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
About Kiniksa Pharmaceuticals International
Pharmaceutical Preparations, SIC 2834
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for debilitating diseases with significant unmet medical need, particularly cardiovascular and autoinflammatory conditions. Its commercial product, ARCALYST, is an interleukin-1 alpha and beta cytokine trap approved in the United States to treat recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes, and Deficiency of Interleukin-1 Receptor Antagonist. The company delivers ARCALYST to patients through a network of specialty pharmacies, while advancing investigational clinical candidates such as KPL-387 for recurrent pericarditis and preclinical programs like KPL-1161.
The company markets its approved therapy throughout the United States, utilizing a specialized internal salesforce. Beyond the United States, it holds worldwide rights to ARCALYST excluding the Middle East and North Africa, having granted development and commercialization rights in the Asia-Pacific territory excluding Japan to a regional partner. The company operates an internal facility to manufacture drug substance for research and early-stage development, while relying on third-party contract manufacturers for late-stage and commercial drug supply. Headquarter details are not stated in the text.
Summary of the business section of Kiniksa Pharmaceuticals International's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Kiniksa Pharmaceuticals International, plc
- Headquarters
- London, United Kingdom
- Address
- 105 Piccadilly, Second Floor W1J 7NJ
- Phone
- (781) 431-9100
- Website
- kiniksa.com
- Employees
- 366, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- KNSA
- Exchange
- Nasdaq
- IPO date
- May 24, 2018
- Shares outstanding
- 157M, Oct 23, 2026
- Public float
- $1.11B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1730430
- CUSIP
- G52694109
- FIGI
- BBG00KT2KFX7
- Share class FIGI
- BBG00KT2KGM7
- EIN
- 98-1795578
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sanj K. Patel | CHAIRMAN & CEO, Director | 1,602,803 |
| John F. Paolini | CHIEF MEDICAL OFFICER | 114,048 |
| Michael R. Megna | CHIEF ACCOUNTING OFFICER | 12,697 |
| Ross Moat | CHIEF OPERATING OFFICER | 10,294 |
| Mark Ragosa | CHIEF FINANCIAL OFFICER | 20,854 |
| Dhiraj H. Malkani | CHIEF STRATEGY OFFICER | – |
| Eben Tessari | CHIEF STRATEGY OFFICER | 23,976 |
| Barry D. Quart | Director | 12,745 |
| Richard S. Levy | Director | 22,359 |
| G. Bradley Cole | Director | 11,672 |
| Bros. Advisors (GP) LLC Baker | Director | 123,820 |
| Brothers Life Sciences LP Baker | Director | 2,745,259 |
| Felix Baker | Director | – |
| Julian Baker | Director | 158,117 |
| Bros. Advisors Lp Baker | Director | – |
| Kimberly J. Popovits | Director | 15,345 |
| Thomas Malley | Director | 87,312 |
| Tracey L. McCain | Director | 15,345 |
| 667, L.P. | Director | 132,566 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $10.78M | $28.44M | $3.51M | $233 | $125 |
| FY2024 | $7.01M | $8.70M | $2.37M | $112 | $91 |
| FY2023 | $5.30M | $6.80M | $1.77M | $99 | $92 |
| FY2022 | $6.11M | $8.73M | $1.92M | $85 | $89 |
| FY2021 | $6.59M | $579.47K | $1.70M | $67 | $99 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Sanj K. Patel Chief Executive Officer and Chairman of the Board | $943.13K | $3.80M | $4.74M | $1.28M | $14.00K | $10.78M | +54% |
| John F. Paolini, M.D., Ph.D. Executive Vice President and Chief Medical Officer | $585.09K | $1.08M | $1.36M | $530.94K | $14.00K | $3.57M | +49% |
| Eben Tessari Executive Vice President and Chief Operating Officer | $586.46K | $1.08M | $1.36M | $533.28K | $5.87K | $3.57M | +54% |
| Ross Moat Executive Vice President and Chief Commercial Officer | $586.27K | $1.08M | $1.36M | $533.33K | $77.78K | $3.64M | +40% |
| Mark Ragosa Senior Vice President and Chief Financial Officer | $552.80K | $978.10K | $1.22M | $516.71K | $14.00K | $3.28M | +51% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 24, 2018
- Offer price
- $18.00
- Securities offered
- 8,477,777
- Gross proceeds
- $152.60M
- Exchange
- Nasdaq
- First trading day
- May 24, 2018
- First-day close
- $19.47+8.2%
- Lock-up ends (est.)
- Nov 20, 2018
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 366 full-time employees, of which 351 were located within the United States and 15 were located outside of the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 28, 2024 | Deregistration | Termination of SEC registration (Form 15) |
| Jun 28, 2024 | Name change | Name changed from Kiniksa Pharmaceuticals, Ltd. to Kiniksa Pharmaceuticals International, plc |
| May 24, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| May 14, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?